Related Experiment Videos
Carcinoid tumours
E M Tiensuu Janson1, K E Oberg
1Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Bailliere'S Clinical Gastroenterology
|December 1, 1996
Summary
Diagnosing carcinoid tumors remains challenging, often leading to late-stage detection. Plasma chromogranin A and U-5-HIAA are key markers for early neuroendocrine tumor diagnosis.
Area of Science:
- Oncology
- Biochemistry
- Medical Diagnostics
Background:
- Carcinoid tumors present significant diagnostic and therapeutic challenges.
- Despite advances in detection methods like PET and scintigraphy, many patients are diagnosed late.
- Diagnosis age has not improved over the last decade.
Purpose of the Study:
- To emphasize the importance of specific biochemical markers for carcinoid tumor diagnosis.
- To review current and potential diagnostic imaging techniques.
- To discuss therapeutic strategies and future directions for carcinoid tumor management.
Main Methods:
- Analysis of plasma chromogranin A and urinary 5-hydroxyindoleacetic acid (U-5-HIAA) for diagnosis.
- Utilizing conventional radiology (CT, MRI, ultrasound) and somatostatin receptor scintigraphy for localization.
- Incorporating endoscopic ultrasound and endoscopy for specific tumor site diagnosis.
Main Results:
- Plasma chromogranin A and U-5-HIAA are sufficient for diagnosing most midgut carcinoid tumors.
- Somatostatin receptor scintigraphy complements conventional imaging for tumor localization.
- Combined aggressive surgery with somatostatin analogues and alpha-interferon improves survival for midgut carcinoids.
Conclusions:
- Early diagnosis of carcinoid tumors relies on appropriate biochemical markers.
- Multimodality imaging is crucial for accurate tumor localization.
- Future treatment strategies require classification based on tumor biology for personalized therapy.